Loading...
NPI 1447987532 · Boca Raton, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Clear Choice Diagnostics Inc is a clinical medical laboratory provider located in Boca Raton, Florida. This profile covers 27 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Clear Choice Diagnostics Inc |
| Address | 6699 N Federal Hwy Ste 105 |
| City | Boca Raton |
| State | FL |
| ZIP | 33487 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 8, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.6M |
| Medicaid | $380 |
CLEAR CHOICE DIAGNOSTICS operates as a genomics-focused clinical laboratory: its Medicare top codes are concentrated in molecular and genetic sequencing (e.g., 81307, 81321, 81249), reflecting services such as BRCA2, PTEN and G6PD sequencing rather than routine anatomic pathology or general chemistry. The presence of many targeted hereditary and oncology genetic codes in the top-25 Medicare list suggests the lab’s operational model centers on specialty diagnostic sequencing panels and single-gene tests used for inherited disease and cancer risk assessment.
Revenue concentration on Medicare is meaningful: the precomputed top 3 Medicare codes (81307, 81321, 81249) account for 35.8% of the provider’s Medicare revenue, with individual shares of 13.2% (81307), 11.8% (81321) and 10.8% (81249). This concentration indicates that a relatively small set of high-value genetic tests drives a large portion of the $7.6M in Medicare revenue reported for this NPI.
Payer mix is effectively single-payer Medicare: the provider reports $7.6M in total Medicare revenue versus $376 in total Medicaid revenue, so Medicaid is negligible in scale for this entity. Medicaid activity is limited to K1034 (COVID self-test) which represents 100.0% of its Medicaid revenue, reinforcing that the organization’s commercial footprint in state programs is minimal.
Competitive standing on core genetic tests is solid but not monopolistic: 81307 ranks #10 of 62 providers nationally (85th percentile), 81321 ranks #7 of 37 (83rd percentile), and 81249 ranks #9 of 62 (87th percentile), all characterized in the source as typical, unremarkable volume for those codes despite high percentile positioning. Those rankings indicate a strong national presence among specialized sequencing providers without implying market dominance across the broader laboratory sector.
There are notable code-level activity signals outside the top-3 mix: 81279 (JAK2 testing) is flagged as notably above typical national volume for this code (rank #10 of 135, 93rd percentile), which suggests the lab also takes meaningful volume in hematology/myeloproliferative testing lines. At the same time a high-claim, lower-dollar programmatic item—K1034—appears in Medicare with 28.9K claims and $346.6K revenue and is described as typical, unremarkable volume for that code, implying substantial distribution or processing of low-unit-value COVID self-tests alongside higher-value sequencing work.
Although the provider’s Medicare code mix shows breadth across oncology, hematology and inherited-disorder testing (examples in the top-25 include 81334, 81311, 81320, 81339, 81345, 81305, and 81351), most of these codes are described as typical, unremarkable volume and occupy mid-to-high national percentiles. This pattern suggests the lab has diversified sequencing capabilities across multiple clinical domains rather than reliance on a single test category.
Medicaid positioning is minimal and narrowly focused: Medicaid billing is effectively limited to K1034 (193 claims, $2 avg paid/claim, $386 revenue), which ranks #60 of 238 in-state (75th percentile) and is characterized as typical, unremarkable volume for this code. The negligible Medicaid revenue ($376) means payers should treat this NPI as functionally Medicare-centric when assessing network strategy or competitive overlap.
The provider has been enumerated relatively recently (NPI registered 2022-08-08, ~4 years ago) yet reports substantial Medicare revenue ($7.6M), indicating rapid scaling in Medicare billing for specialty genetic services. For payer analysts, that tenure plus the concentrated high-dollar genetic testing mix suggests a laboratory that has quickly established contracting relationships or referral pathways into Medicare populations for specialized molecular diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
27 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 1,520 | $660 | $1M |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 1,530 | $590 | $899.6K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 1,410 | $590 | $827.9K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 1,380 | $590 | $811.4K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,410 | $490 | $689K |
| 81334 | The lab analyst performs the technical lab test to detect the presence of specific changes in the runt related transcription factor 1 (RUNX) gene for targeted sequence analysis, such as exons 3–8. | 1,440 | $320 | $465.4K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 1,440 | $290 | $417.9K |
| 81320 | The lab analyst performs the technical lab test to detect the presence of common changes in the phospholipase C gamma 2 gene (PLCG2). | 1,440 | $290 | $412.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 28,880 | $10 | $346.6K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 1,440 | $180 | $262.3K |
Showing 1–10 of 27
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
27 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 5 | 30 | 320 | $660 | $508.3K |
| 81321 | 6 | 30 | 430 | $580 | $467.7K |
| 81238 | 5 | 20 | 330 | $590 | $440.3K |
| 81162 | 8 | 20 | 100 | $1,780 | $403.3K |
| 81249 | 5 | 20 | 290 | $590 | $383.1K |
| 81223 | 5 | 20 | 340 | $490 | $329.3K |
| 81351 | 12 | 20 | 210 | $630 | $307.8K |
| 81334 | 5 | 20 | 390 | $320 | $295.7K |
| 81311 | 4 | 20 | 270 | $290 | $213K |
| 81320 | 5 | 20 | 210 | $290 | $210.6K |
Showing 1–10 of 27
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 190 | $1 | $390 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 60 | 240 | 60 | $1 | $330 |
Other providers in the same ZIP code as Clear Choice Diagnostics Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Trusted Home Care Services Nurse Registry | FL | Home Health Agency | $0 | $27.9M |
| Dialyze Direct Fl LLC | FL | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $16.6M |
| Us Path Labs LLC | FL | Clinical Medical Laboratory | $2.3M | $16.9K |
| City Of Boca Raton Office | FL | Ambulance | $1.3M | $612.7K |
| Joshua Weiss | FL | Otolaryngology Physician | $619.3K | $0 |
| Ashley Bowles | FL | Foot & Ankle Surgery Podiatrist | $562.7K | $0 |
| David Schwartzwald | FL | Urology Physician | $557.7K | $0 |
| Jillian Frieder | FL | Dermatology Physician | $525.8K | $0 |
| Michael Aronsohn | FL | Specialist | $492.9K | $0 |
| Fernando Recio | FL | Hematology & Oncology Physician | $456.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.